Terlipressin Hrs denied as experimental or investigational by Humana?

Humana's specific coverage criteria for terlipressin hrs are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Terlipressin as Experimental — and Why That's Wrong

Terlipressin received FDA approval for hepatorenal syndrome type 1 (HRS-1). Despite this, Humana may issue an "experimental or investigational" denial if its coverage policy has not been updated to reflect the FDA approval, if the policy is being applied to a use that the reviewer considers off-label, or if an outdated policy template is triggering the denial.

### Why This Denial Happens

Insurers often lag behind FDA approval dates when updating internal coverage policies. An experimental denial can also arise when the billing code or diagnosis code pairing is unfamiliar to the reviewer, or when coverage criteria have not yet been formally published for the newly approved indication. In HRS-1, which is a rare and serious condition, this lag creates real access barriers.

### Why It's Appealable

An experimental denial for an FDA-approved drug used within its approved indication is among the most straightforwardly reversible denial types. FDA approval is the foundational standard for most commercial payer coverage determinations. Under ACA §2719 external-review rights and ERISA §503, you are entitled to have an independent physician reviewer — not Humana's internal reviewer — assess whether the denial is supported by clinical evidence. File for external review within approximately four months of the denial. Expedited review is available if urgency is documented.

### Concrete Appeal Process

1. Confirm the FDA approval — Pull the current FDA prescribing label for terlipressin (available at DailyMed or the FDA label repository) and attach it to your appeal as Exhibit A. 2. Request Humana's policy — Ask for the written coverage policy applied and its effective date; compare it against the FDA approval date. 3. Internal appeal — File with the label and a prescriber letter; argue that FDA approval negates the experimental classification. 4. External review — An independent reviewer is highly likely to reverse an experimental denial for an FDA-approved drug in its labeled indication. File as soon as the internal appeal is denied.

### Documentation to Gather

• FDA approval documentation — the current prescribing information confirming approval status and the approved indication for HRS-1.
• Diagnosis confirmation — hepatologist or intensivist notes, laboratory data trend, and documented HRS-1 diagnosis meeting the criteria described in the prescribing label.
• Clinical severity documentation — chart notes reflecting the acuity of the patient's condition and the urgency of treatment.
• Prescriber medical-necessity letter — the treating physician should state that the requested use is within the FDA-approved indication and is consistent with the applicable professional society clinical practice guideline (such as AASLD guidance on HRS).

### Criteria-Mapping Structure

Create a two-column table. Left column: each basis Humana cited for the experimental determination. Right column: the specific rebuttal — FDA approval date, the approved indication text, and the chart fact confirming the patient meets that indication. Showing this mapping explicitly, rather than arguing in narrative, removes ambiguity and forces a documented response to each point.